Is it the Same for Mounjaro?

Understanding the coverage and appeal process for Mounjaro in comparison to other GLP-1 medications.

Coverage and Prior Authorization for Mounjaro

Mounjaro (tirzepatide) is a GLP-1 medication that is generally covered more readily for Type 2 diabetes. If you have a diabetes diagnosis, it is advisable to frame the request for Mounjaro in that context, as this can improve the chances of approval.

Similar to other GLP-1 medications, Mounjaro may require prior authorization (PA) based on specific criteria. Most plans typically require a qualifying BMI (≥30 for obesity or ≥27 with at least one weight-related condition) and documented participation in a reduced-calorie diet and increased physical activity. Additionally, some plans may require step therapy, where a preferred or cheaper drug must be tried first.

Denial Reasons for Mounjaro

Denials for Mounjaro can occur for similar reasons as other GLP-1 medications. Common reasons include the plan excluding weight-loss drugs entirely, lack of documentation for BMI or comorbidities, and missing required diet or lifestyle program documentation. If Mounjaro is requested for an off-label use, such as for weight loss when it is primarily indicated for diabetes, this may also lead to denial.

It's important to ensure that all required documentation is submitted with the request to avoid these common pitfalls.

Appealing a Denial for Mounjaro

If a request for Mounjaro is denied, the appeal process is similar to that for other GLP-1 medications. The first step is to submit an internal appeal, which may include a letter of medical necessity that ties your documented record to the plan's criteria. A peer-to-peer review can also be requested, where your prescriber speaks directly with the plan's medical director. If the denial persists, further appeals can be made with additional documentation or through an external review by a neutral third party.